TRIALSITEIQ PUBLIC FEASIBILITY SCORECARD · GRADE C

NCT07387367: A Phase 3 Trial to Compare IV BCV Versus IV CDV for Treatment of Adenovirus Infection After Allo-HCT

Sponsor: SymBio Pharmaceuticals · Phase: PHASE3 · Area: INFECTIOUS_VACCINE · Target Enrollment: 180 pts

Competing Trials Overlap

14 Active Trials

Excess Burn Exposure

$3,214,596

Rescue Site Savings

+$2,129,148

Unlock Full NCT07387367 Backup Super-Site Packet ($49 One-Time Pass)

Download the complete list of top-decile low-cannibalization clinical sites, verified Principal Investigator (PI) direct emails/phones, and protocol optimization benchmarks.

Download $49 NCT07387367 Rescue Dossier →